Interestingly, while all RAS-mutant MLL-rearranged ALL patient samples are susceptible to MEK inhibition, patients without RAS mutations also might benefit from MEK inhibitor treatment, since a subgroup of RAS-wildtype patient samples appears sensitive to MEK inhibition. Here, KMT2A is linked to acute lymphoblastic leukemia.